For decades, memory loss has been treated as the public face of cognitive decline. A forgotten name, a misplaced key, a repeated question — these have been the familiar warning signs families watch for. But a growing body of brain-health research is shifting attention from the mind alone to the body in motion.
The emerging question is both simple and profound: can the way a person walks, turns, balances, or slows down reveal early signs of cognitive decline before obvious memory symptoms appear?
The answer, according to recent research, is increasingly: possibly, yes — but with caution.
Dementia remains one of the world’s most urgent health challenges. The World Health Organization estimates that 57 million people were living with dementia in 2021, with nearly 10 million new cases every year. Alzheimer’s disease is the most common form, contributing to an estimated 60% to 70% of dementia cases.
Against that backdrop, scientists are searching for earlier, cheaper, and less invasive warning signals. Brain scans and laboratory biomarkers can detect Alzheimer’s-related changes, but they are expensive, inaccessible for many populations, and often used only after symptoms have already raised concern. Movement, by contrast, is observable every day.
The next frontier in brain health may not begin inside a hospital scanner. It may begin with a quiet change in stride.
Why walking is not just physical
Walking appears automatic, but it is neurologically demanding. It requires coordination between attention, executive function, balance, motor planning, vision, and reaction time. When the brain begins to change, the body may compensate long before the person notices memory loss.
Recent reviews of gait and Alzheimer’s research argue that gait parameters may serve as early indicators of cognitive impairment. A 2025 review in Frontiers in Neurology noted that reduced mobility and slower gait can predict later cognitive deterioration, while cognitive decline itself can also worsen mobility and fall risk — making the relationship bidirectional rather than incidental.
That matters because clinical dementia detection often happens late. If subtle changes in walking speed, stride variability, turning behavior, balance, or dual-task walking can be measured reliably, doctors may one day have another practical layer of screening.
The body may be writing neurological clues in motion — one shortened step, one slower turn, one unstable balance correction at a time.
The rise of digital movement biomarkers
The phrase now gaining ground is digital biomarkers — measurable physiological or behavioral data captured by phones, wearables, sensors, smart insoles, or other digital devices. In Alzheimer’s research, these can include gait patterns, sleep signals, speech changes, eye movements, and daily activity patterns. A 2025 npj Digital Medicine review described digital biomarkers as objective data collected through digital devices, including gait parameters from wearables, eye tracking, and speech features.
Wearables are especially attractive because they can measure people in real life, not only during a short clinic visit. A patient may walk normally for 20 seconds in front of a doctor but show meaningful changes over weeks of daily movement. Continuous monitoring could reveal patterns that traditional assessments miss.
A 2025 bibliometric review in Sensors found that wearable sensor technologies and gait analysis have become a growing research area for early dementia detection, mapping studies from 2010 to 2025 and emphasizing movement-related biomarkers in Alzheimer’s and dementia research.
The data can be surprisingly rich: step length, cadence, walking speed, pressure distribution, balance sway, turning velocity, pauses, asymmetry, variability, and how walking changes when the person is also talking or solving a mental task.
Dual-task walking: when the brain has to multitask
One of the most revealing tests is known as dual-task walking. A person is asked to walk while performing another cognitive task — for example, counting backwards, naming words, or holding a conversation. In healthy movement, the brain manages both tasks smoothly. But when executive function weakens, walking may slow, turning may become unstable, or stride rhythm may become irregular.
A 2024 study in Frontiers in Aging Neuroscience investigated wearable-based digital gait biomarkers for distinguishing mild cognitive impairment and dementia, focusing on dual-task turn velocity as a potential signal.
This is important because everyday life is full of dual-task movement. People rarely walk in laboratory silence. They walk while crossing roads, carrying groceries, answering questions, checking phones, navigating crowds, or climbing stairs. Cognitive decline may reveal itself first when the brain is forced to divide attention.
A normal walk may hide decline. A distracted walk may expose it.
The step-count breakthrough: movement as protection, not only prediction
Movement patterns are not only being studied as warning signals. They are also being studied as possible protective factors.
In November 2025, a Nature Medicine study using data from the Harvard Aging Brain Study reported that, among cognitively unimpaired older adults with elevated amyloid, even 3,001 to 5,000 steps per day were associated with slower tau accumulation and slower cognitive and functional decline. The study found further benefit at 5,001 to 7,500 steps per day, with effects appearing to plateau above that range.
Harvard’s public summary of the study stated that cognitive decline was delayed by about three years for those walking 3,000 to 5,000 steps daily and by about seven years for those walking 5,000 to 7,500 steps daily, compared with sedentary individuals.
The finding does not prove that walking alone prevents Alzheimer’s. The study was observational, and healthier people may also be more likely to walk. But it strengthens a growing view: daily movement may be both a brain-health marker and a modifiable lifestyle lever.
Smart insoles and the future of invisible screening
One of the most striking recent developments is the rise of smart gait technology embedded into everyday objects.
In 2025, researchers reported a wireless, self-powered smart insole in Science Advances designed for plantar pressure monitoring, real-time visualization, and gait analysis. Ohio State University described the system as a smart insole that can track how people walk, run, and stand in real time, with potential use in posture monitoring and early warnings for health conditions.
Such technologies point toward a future where brain-health screening could become passive and continuous. Shoes, watches, phones, home sensors, or rehabilitation platforms may collect movement data in the background. AI models could then identify changes that warrant clinical follow-up.
But that future also raises ethical and regulatory questions. Who owns the data? Can insurers access it? Could an algorithm incorrectly label someone as cognitively impaired? How will systems avoid bias across age groups, body types, disabilities, cultures, and mobility conditions?
A movement biomarker is powerful only if it is accurate, fair, private, and clinically meaningful.
The market is moving fast
The commercial momentum is already visible. The digital brain-health market is expanding as wearables, remote monitoring, AI analytics, and preventive health tools converge. One 2026 market estimate placed the global digital brain-health market at USD 248.62 billion in 2025, with projections approaching USD 478.53 billion by 2034.
Brain-health devices are also attracting attention. A 2026 market estimate projected the global brain-health devices market at USD 17.84 billion in 2026, rising to USD 32.20 billion by 2033.
The opportunity is clear: aging populations, rising dementia prevalence, overwhelmed healthcare systems, and consumer adoption of wearables are creating demand for earlier detection tools. The challenge is just as clear: healthcare cannot afford another wave of wellness gadgets that produce attractive dashboards but weak clinical evidence.
What the research can — and cannot — say today
The science is promising, but it is not yet definitive enough to treat gait data as a standalone diagnostic tool for dementia.
Movement changes can be caused by many factors: arthritis, neuropathy, Parkinson’s disease, stroke, medication side effects, depression, poor sleep, vision problems, frailty, pain, cardiovascular disease, or simple deconditioning. A slower walk does not automatically mean cognitive decline.
The strongest near-term use case is not replacing doctors. It is risk screening, longitudinal monitoring, rehabilitation planning, and early referral.
A person whose walking speed, balance, turn stability, and dual-task performance decline over time may benefit from cognitive assessment, neurological review, fall-risk evaluation, medication review, and lifestyle intervention. In that sense, movement data could become a practical early-warning layer.
The promise is not that a smartwatch will diagnose dementia. The promise is that everyday movement may help identify who needs attention sooner.
A new model of brain health
The larger shift is philosophical. Brain health is no longer being viewed only through memory tests and clinic visits. It is becoming a continuous, whole-body signal involving sleep, activity, gait, balance, speech, mood, cardiovascular health, and daily function.
The 2025 World Alzheimer Report focused on rehabilitation and the importance of helping people with dementia maintain function, independence, and participation. Movement-based monitoring fits naturally into that broader future: not only detecting decline, but supporting people earlier and preserving quality of life longer.
For families, the message is practical. Watch not only what an older person forgets, but also how they move. Are they slowing noticeably? Avoiding stairs? Taking shorter steps? Becoming unstable when turning? Struggling to walk while talking? Falling more often? These signs do not confirm dementia, but they deserve attention.
For healthcare systems, the message is strategic. Low-cost movement screening could help identify risk earlier, especially in countries where access to advanced imaging is limited.
For researchers and technology companies, the message is urgent. The race is no longer just to collect movement data. It is to prove which signals matter, for whom, under what conditions, and how they can improve outcomes.
Conclusion
Movement may become one of the most important windows into the aging brain. The evidence linking gait, step count, balance, and cognitive decline is growing, and wearable technology is making these signals easier to capture outside the clinic.
But the field must move carefully. Prediction is not diagnosis. Correlation is not causation. A walking pattern is a clue, not a verdict.
Still, the direction of travel is unmistakable. The future of brain-health research may be measured not only in scans and blood tests, but in the rhythm of daily life — the pace of a morning walk, the steadiness of a turn, the confidence of a step.
